San Diego, Ca., USA - March 4, 2014, San Diego, Ca., USA - Celladon Corporation, a clinical-stage biotechnology company, announced it has appointed Peter K. Honig and Patrick Y. Yang to its board of directors.
Article continues below
Dr. Honig currently serves as the Head of Global Regulatory Affairs at AstraZeneca, Inc., a global innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines.
Prior to this position, Dr. Honig served as Senior Vice President, Worldwide Regulatory Affairs and Product Safety at Merck & Company. Dr. Honig was Merck's Vice President, Worldwide Product Safety and Quality Assurance. Prior to Merck, Dr. Honig held various positions at the FDA including Director of the Office of Drug Safety in the FDA's Center for Drug Evaluation and Research.
Dr. Honig received his B.A. in History from Columbia College of Columbia University, his M.D. from the Columbia College of Physicians & Surgeons and his M.P.H from Columbia University School of Public Health. He also serves as a director of Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity.
Dr. Yang recently retired from F. Hoffman-La Roche AG, a global pharmaceutical and diagnostics company, where he served as Global Head of Pharmaceutical Technical Operations based in Switzerland. In this role, Dr. Yang was responsible for Roche's pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management, distribution, and procurement functions.
Previously, Dr. Yang worked for Genentech, a biotechnology company, where his most recent position was Executive Vice President of Product Operations, responsible for Genentech's manufacturing, engineering, process development, regulatory, quality, compliance, and supply chain management functions.
Prior to Genentech, Dr. Yang held several leadership roles at Merck, including Vice President of Asia/Pacific Operations and Vice President of Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. in research, development, and manufacturing operations.
Dr. Yang currently serves on the board of directors of Tesoro Corporation, an independent refiner and marketer of petroleum products, and on the board of directors of Codexis, Inc., a company in the development and production of custom industrial enzymes for use in the pharmaceutical, chemical and biofuel production.
The company also announced that concurrent with these appointments, Johan Kördel will step down from his current role as director.
Dr. Kördel has been a Senior Partner at Lundbeckfond Invest A/S since 2010. He is Senior Partner at Lundbeckfond Ventures. He worked almost a decade in the pharmaceutical company Pharmacia with management, research, early development, portfolio management, business development and alliance management. He served as a Director of the Metabolic Diseases project portfolio and Deputy Head of Metabolic Diseases Research at Pharmacia from 1992 to 2000. He was previously Co-founder and Chief Executive Officer at Sound Biotech ApS.
Dr. Kördel co-founded Biovitrum in 2001. He served as a Project Director of Pharmacia. He served as a Senior Vice President of Research at Biovitrum from 2001 to 2003 and served as its Senior Vice President of Business Development from 2004 to 2005. He co-founded a number of companies. He worked at Scripps Research Institute, La Jolla, United States and Harvard Medical School, Boston, USA. Dr. Kördel serves as the Chairman of the Chori Pars AB.
He has been Director of Celladon Corporation since January 2012, Enterome SA, Syntaxin Ltd., Acacia Pharma Limited and Respiratorius AB. Dr. Kördel has been a Director of River Vision Development Corp. since December 12, 2012. He served as a Deputy Director of BoneSupport AB. He served as a Director of Karo Bio Aktiebolag (publ) since July 2009.
He served as a Director of iNovacia AB and InDex Pharmaceuticals AB. He served as a Director of Sound Biotech A/S. He serves as a Director at EQL Pharma AB. He has been an Associate Professor of Lund University - Department of Physical Chemistry since 1994. ■